health news today obesity drugs glp-1 pharma october 2025 Outlook for obesity in 2025: more Use of GLP-1 Drugs to

A review of the relevant literature and the National Institute of Health clinical trial registry did not yield evidence that such a study has been published or is currently underway

Over time, the benefits of these drugs led to newer and advanced products, Wegovy and Zepbound, to be introduced to market specifically targeting obesity

Therefore, these equations cannot be used in patients with exogenous insulin use (38)

Approved for weight management as Saxenda, it requires daily injections rather than weekly, which is a significant practical difference

In: ISPOR [Internet] 2025

These guidelines, grounded in consensus and clinical experience rather than rigorous research, have long been a cornerstone of safe anesthesia practice (Joshi et al